



TEST REPORT NO 323934/24/GDY

Client 7FIT S.A. Stanowice 82A 55-200 Stanowice			Sample (according to declaration of Client) Sample description: 7NUTRITION OMEGA 3 110 softgels Batch: 280324.1 Production date: 28.03.2024 Expiry date: 30.04.2026			
Sample reception date:	01.06.2024		Sample status: no objections			
Start of analysis	03.06.2024		. ,			
End of analysis	01.07.2024		Controls received from the Olient			
Test report date 01.07.2024 S		Sample received from the Client				
Test Method		Unit	Result	Criteria	Statement of conformity	
Fatty acids profile ^{1) 3)} PN-EN ISO 12966-1:2015-01;	PN-EN ISO 12966-2:2	2017-05 except p.5	5.3 and 5.5; PN-EN ISO 12966-4:201	15-07		
C4:0 butyric acid		mg/capsule filling	< 1 (1 ± 1)	-	-	
C6:0 caproic acid		mg/capsule filling	ر < 1 (1 ± 1)	-	-	
C8:0 caprylic acid		mg/capsule filling	ı < 1 (1 ± 1)	-	-	
C10:0 capric acid		mg/capsule filling	< 1 (1 ± 1)	-	-	
C11:0 undecylic acid		mg/capsule filling	< 1 (1 ± 1)	-	-	
C12:0 lauric acid		mg/capsule filling	ı < 1 (1 ± 1)	-	-	
C13:0 tridecylic acid		mg/capsule filling	ا < 1 (1 ± 1)	-	-	
C14:0 myristic acid		mg/capsule filling	9 ± 1	-	-	
C14:1 myristoleic acid		mg/capsule filling	ا < 1 (1 ± 1)	-	-	
C15:0 pentadecanoic acid		mg/capsule filling	ا < 1 (1 ± 1)	-	-	
C15:1 ginkgolic acid		mg/capsule filling	ا < 1 (1 ± 1)	-	-	
C16:0 palmitic acid		mg/capsule filling	45 ± 5	-	-	
C16:1n7 palmitoleic acid		mg/capsule filling	18 ± 2	-	-	
C16:1 (sum of)		mg/capsule filling		-	-	
C17:0 margaric acid		mg/capsule filling	1 3 ± 1	-	-	
C16:2n4 hexadecadienoic acid		mg/capsule filling	2 ± 1	-	-	
C17:1 margaroleic acid		mg/capsule filling	<pre>1 (1 ± 1)</pre>	-	-	
C16:3n4 hexadecatrienoic acid		mg/capsule filling	1 3 ± 1	-	-	
C18:0 stearic acid		mg/capsule filling	40 ± 4	-	-	
C18:1n9 trans elaidic acid		mg/capsule filling	1 ± 1	-	-	
C18:1n9 oleic acid		mg/capsule filling		-	-	
C18:1n7 vaccenic acid		mg/capsule filling		-	-	
C18:1 (sum of)		mg/capsule filling	115 ± 15	-	-	
C18:2n6 trans linolelaidic acid		mg/capsule filling	< 1 (1 ± 1)	-	-	
C18:2 trans (sum of)		mg/capsule filling	1 8 ± 1	-	-	

Page 1/3





TEST REPORT NO 323934/24/GDY

nsoluble impurities	%	<0,1	-	-
nsoluble impurities PN-EN ISO 663:2017-03				
Water PN-EN ISO 8534:2017-03	% (w/w)	0,06	-	-
Fotal Omega-9 fatty acids ²⁾	mg/capsule filling	98 ± 13	-	-
Fotal Omega-6 fatty acids ²⁾	mg/capsule filling	35 ± 5	-	-
Fotal Omega-3 fatty acids ²⁾	mg/capsule filling	638 ± 83	-	-
Sum of trans fatty acids isomers	mg/capsule filling	9 ± 1	-	-
Fotal polyunsaturated fatty acids (PUFA) ²⁾	mg/capsule filling	677 ± 88	-	-
Fotal monounsaturated fatty acids (MUFA) ²⁾	mg/capsule filling	157 ± 20	-	-
Total saturated fatty acids (SAFA)	mg/capsule filling	107 ± 14	-	-
Other fatty acids	mg/capsule filling	50 ± 7	-	-
C22:6n3 docosahexaenoic acid (DHA)	mg/capsule filling	217 ± 22	-	-
C22:5n3 docosapentaenoic acid (DPA)	mg/capsule filling	33 ± 3	-	-
C24:1n9 nervonic acid	mg/capsule filling	4 ± 1	-	-
C24:0 lignoceric acid	mg/capsule filling	< 1 (1 ± 1)	-	-
C20:5n3 eicosapentaenoic acid (EPA)	mg/capsule filling	337 ± 34	-	-
C20:4n3 eicosatetraenoic acid (ETA)	mg/capsule filling	15 ± 2	-	-
C22:2n6 docosadienoic acid	mg/capsule filling	< 1 (1 ± 1)	-	-
C23:0 tricosylic acid	mg/capsule filling	3 ± 1	-	-
C20:4n6 arachidonic acid (ARA)	mg/capsule filling	13 ± 1	-	-
C20:3n3 eicosatrienoic acid (ETE)	mg/capsule filling	2 ± 1	-	-
C22:1 (sum of)	mg/capsule filling	6 ± 1	-	-
C22:1n9 erucic acid	mg/capsule filling	3 ± 1	-	-
C22:1n11 gadoleic acid	mg/capsule filling	3 ± 1	-	-
C20:3n6 dihomo-γ-linolenic acid	mg/capsule filling	3 ± 1	-	-
C22:0 behenic acid	mg/capsule filling	2 ± 1	-	-
C20:2n6 eicosadienoic acid	mg/capsule filling	3 ± 1	-	-
C18:4n3 stearidonic acid (SDA)	mg/capsule filling	28 ± 3	-	-
C18:3 (sum of)	mg/capsule filling	8 ± 1	-	-
C18:3n3 α-linolenic acid (ALA)	mg/capsule filling	6 ± 1	-	-
C20:1 (sum of)	mg/capsule filling	16 ± 2	-	-
C20:1 eicosenoic acid	mg/capsule filling	14 ± 1	-	-
C18:3n4 octadecatrienoic acid	mg/capsule filling	< 1 (1 ± 1)	-	-
C21:0 heneicosanoic acid	mg/capsule filling	< 1 (1 ± 1)	-	-
C18:3n6 γ-linolenic acid (GLA)	mg/capsule filling	2 ± 1	-	-
C20:0 arachidic acid	mg/capsule filling	5 ± 1	-	-
C18:2n6 linoleic acid (LA)	mg/capsule filling	13 ± 1	-	-

Page 2/3





TEST REPORT NO 323934/24/GDY

Insoluble impurities	g/100 g	<0,1	-	-
Total fatty matter BS 684-2.4:1976				
Total fath - matter	%	99,65 ± 4,98	-	-
Total fatty matter	g/100 g	99,65 ± 4,98	-	-
Ash ISO 6884:1985 (withdrawn)				
٨-٢	%	0,29 ± 0,02	-	-
Ash	g/100 g	0,29 ± 0,02	-	-

¹⁾ Capsule filling weight declared by the Client: 1005 mg.

²⁾ Results of individual summs of unsaturated fatty acids do not include the content of trans fatty acids.

³⁾ The lower limit of the measuring range of the accredited method, which is also the limit of quantification set by the Laboratory.

Authorized by:

- ID: 53, Fuel Laboratory Manager Gdynia, Fuel Laboratory
- ID: 98, Analysis Expert, Gas Chromatography Laboratory

ID: 346, Analysis Expert, Nutrition Analysis Laboratory

ID: 383, Analysis Expert, Classical Analysis Laboratory ID: 548, Analysis Expert, Classical Analysis Laboratory

The test report bears the certified electronic seal of J.S. Hamilton Poland Sp. z o.o.

Laboratory address:

Chwaszczyńska 180, 81-571 Gdynia

The results refer only to the samples received. When a measurement uncertainty is given, it is an expanded uncertainty estimated for a coverage factor k=2 at 95% confidence level and is not including sampling uncertainty, unless otherwise stated. When the conformity is stated J.S. Hamilton Poland Sp. z o.o. applies the simple acceptance decision rule in accordance with ILAC-G8:09/2019, unless otherwise reported. If the "result" column of the accredited method, whereas the given expanded measurement uncertainty relates only to the lower or upper limit of the measuring range of the accredited method, whereas the given expanded measurement uncertainty relates only to the lower or upper limit of the measuring range of the accredited method, whereas the given expanded measurement uncertainty relates only to the lower or upper limit of the measuring range of the accredited method interpretation in the "statement of conformity" column, which is based on the obtained test outcome. This test report may not be copied in part without the prior written permission of J.S. Hamilton Poland Sp. z o.o. the responsibility of J.S. Hamilton Poland Sp. z o.o. is limited solely to the data issued in its original. J.S. Hamilton Poland Sp. z o.o. does not permit the use of the PCA accreditation symbol AB 079 by customers, subcontractors, external service providers and other third parties. For further information please refer to the PCA document - DA-02. The service confirmed by this report is subject to the General Terms and Conditions of Services of J.S. Hamilton Poland Sp. z o.o. published on www.hamilton.com.pl. * Test method accredited

Test performed by external provider

THE END OF THE REPORT

Page 3/3